Valencia, Spain, Oct. 9, 2025 -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following investor and industry events:
- 5th Annual Needham Private Biotech and MedTech Company Virtual 1x1 Forum
- October 14-15, 2025 (virtual)
- Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference
- Chardan/Sanofi: The Double Helix Den: A closed-door symposium enabling unfiltered conversations on genetic medicines
- October 20, 2025, New York, NY
- Mr. Legros will be participating in a panel discussion titled "Clinical stage development: Balancing safety and maximizing clinical benefit"
- Chardan's 9th Annual Genetics Medicines Conference
- October 21, 2025, New York, NY
- Mr. Legros will participate in one-on-one meetings with investors during the conference
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases.
The Company headquarters are in Valencia, Spain.
For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov. For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
|
Company Contact. |
Investor and This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology. |
